S. boulardii is a commonly prescribed probiotic that can prevent or improve a number of GI issues. This probiotic also combats bacterial, parasite and fungal infections, and exhibits other important benefits.
What is Saccharomyces boulardii?
Saccharomyces boulardii is a tropical species of yeast first isolated from lychee and mangosteen fruit in 1923. A French scientist (named Boulard, hence the scientific name of S. boulardii) first isolated this yeast after observing the natives of Southeast Asia chewing on the skin of lychee and mangosteen in an attempt to ward off cholera.
S. boulardii has been prescribed in the past 30 years for the prevention and treatment of diarrheal diseases caused by bacteria. Evidence suggest that this probiotic may be beneficial for IBD (R) and IBS patients.
Health Benefits of S. boulardii
1) S. boulardii is Beneficial for the GI Tract
S. boulardii Prevents and Treats Diarrhea
S. boulardii is safe and has clear beneficial effects in children who have acute diarrhea (R).
S. boulardii significantly reduces the frequency and duration of acute diarrhea in children. This probiotic is well-tolerated (R,R,R,R,R,R). It also often reduces the length of ECU and hospital stay in acute infectious gastroenteritis in children (R,R).
Some studies report that S. boulardii is not effective in preventing the development of antibiotic-associated diarrhea (R,R,R,R). However, many studies do, in fact, show that S. boulardii is effective in reducing the risk of antibiotic-associated diarrhea in both children and adults (R,R,R,R,R,R,R).
S. boulardii was also found to prevent traveler’s diarrhea, particularly in regions such as North Africa and in the Near-east (R).
S. boulardii Improves IBS
S. boulardii improved the quality of life in patients with diarrhea-predominant IBS or mixed-type IBS (R).
One study, however, found no improvement in IBS-D patients after S. boulardii treatment (R).
S. boulardii May Alleviate Drug-induced GI Damage
S. boulardii significantly reduced the numbers of gastric ulcers and the ulceration surface of the gastric mucosa in rats treated with ibuprofen (R).
S. boulardii May Ameliorate IBD
S. boulardii can be an effective addition in the treatment of patients with ulcerative colitis (R).
In association with doxycycline it is effective in treating IBD in animal models, in which doxycycline is used to induce remission and long-term probiotic administration helps to prevent the relapses (R).
S. boulardii reduces inflammation and intestinal colonization by C. albicans in mice with colitis (R).
S. boulardii is Beneficial in Crohn’s Disease
S. boulardii added to baseline therapy improved intestinal permeability in Crohn’s disease (CD) patients, even though complete normalization was not achieved (R).
In addition to the basic treatment, it reduced the frequency of bowel movements in CD patients (R).
S. boulardii Relieves GI Inflammation
S. boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in mice with intestinal mucositis (R).
S. boulardii inhibits C. difficile toxin A-associated enteritis and protects against intestinal inflammation in mice (R).
2) S. boulardii is Beneficial in H. pylori Therapy
S. boulardii has a positive effect on reducing the colonization of H. pylori in the human gastrointestinal system but is not capable of its eradication when used as single therapy (R).
In patients with H. pylori infection, there is evidence to recommend the use of S. boulardii along with standard triple therapy as an option for increasing the eradication rates and decreasing overall therapy-related side effects, particularly diarrhea (R,R,R,R,R,R).
S. boulardii administered in addition to proton pump inhibitor-based triple therapy nonsignificantly lowered the incidence of nausea, vomiting, and abdominal pain and significantly lowered the incidence of stomatitis, constipation, and diarrhea in infected children (R).
S. boulardii improved anti-H. pylori therapy-associated diarrhea, epigastric discomfort, and treatment tolerability. In addition, S. boulardii decreased post-treatment dyspepsia symptoms independent of H. pylori status (R).
3) S. boulardii Combats Bacterial, Parasite and Fungal Infections
S. boulardii reduces E. coli numbers in children (R).
S. boulardii increased survival rate, protected against liver damage and inhibited the translocation of bacteria in mice infected with typhoid fever (Salmonella enterica Typhimurium) (R).
S. boulardii can treat B. hominis infection in children as efficiently as metronidazole (R).
S. boulardii was effective in treating giardiasis when combined with metronidazole therapy in adult patients (R).
The addition of S. boulardii to metronidazole in amebiasis significantly decreases the duration of (bloody) diarrhea and enhances clearance of cysts in children (R), and decreases the duration of symptoms and cyst passage in adults (R).
One study, however, found no benefit of S. boulardii in amebiasis- treatment (R).
S. boulardii decreases C. albicans adhesion and reduces cytokine-mediated inflammatory host response (R).
Prophylactic S. boulardii supplementation is as effective as nystatin in reducing fungal colonization and invasive fungal infection, more effective in reducing the incidence of clinical sepsis and the number of sepsis attacks and has a favorable effect on feeding intolerance in very low birth weight infants(R).
4) S. boulardii Boosts the Immune Response
S. boulardii enhances the immune response in pediatric acute gastroenteritis (R).
Oral treatment with viable or heat-killed cells of S. boulardii maintains the intestinal integrity and modulates the immune system in mice, preventing bacterial translocation and intestinal lesions (R).
5) S. boulardii Increases Feeding Tolerance in Infants
Prophylactic supplementation of S. boulardii improved weight gain, improved feeding tolerance, and had no adverse effects in preterm infants >30 weeks old (R).
Orally administered S. boulardii reduces feeding intolerance and clinical sepsis in very-low-birth-weight (VLBW) infants (R).
6) S. boulardii May Help Prevent Cardiovascular Disease
Daily supplementation with S. boulardii lowered remnant lipoprotein in hypercholesterolemic adults, a predictive biomarker and potential therapeutic target in the treatment and prevention of coronary artery disease (R).
7) S. boulardii May be Beneficial in Diabetes and Obesity
8) S. boulardii May Improve Liver Health
S. boulardii promotes liver function and slows down the progress of liver fibrosis in rats (R).
S. boulardii effectively prevents liver injury induced by Salmonella Enteritidis infection in mice (R).
S. boulardii ameliorates intestinal injury and the accompanying liver inflammation by supporting the antioxidant state of the tissues and by inhibiting the recruitment of neutrophils (R).
9) S. boulardii May be Beneficial in HIV Patients
Treatment with S. boulardii decreases microbial translocation (LBP) and inflammation parameters in HIV-1-infected patients with long-term virologic suppression (R).
- S. boulardii decreases pro-inflammatory cytokines TNF-α (R,R,R,R,R), IL-1β (R,R,R) and IL-6 (R,R).
- S. boulardii decreases IL-8 (R,R ,R ,R , R) (a study where IL-8 was increased: R).
- S. boulardii increases the anti-inflammatory cytokine IL-10 (R, R ,R) (in some tissues IL-10 may be decreased: R).
- S. boulardii can both increase (R) and decrease (R) TGF-beta.
- S. boulardii can both decrease (R) and increases IFN-γ (R, R).
- S. boulardii increases IgA (R ,R), can increase CD8 lymphocytes (R) and TLR2 and TLR4 (R).
- S. boulardii increases GSH (R).
- S. boulardii decreases CXCL1 (R), CRP (R) and NF-kappaB (R, R).
- S. boulardii can both increase and decreases PPAR-γ (R, R).
- S. boulardii decreases COL1A1, αSMA, AST, ALT and MDA (R).
S. boulardii is safe for use in otherwise healthy populations and was even shown to be safe in patients infected with HIV-1 (R).
However, fungemia is a rare but serious complication of treatment with S. boulardii, and this probiotic should be taken with care or avoided in immunocompromised patients (R).